Trials / Unknown
UnknownNCT01051765
Irinotecan Combined With Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer : a Single Center Prospective Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Irinotecan, as one new agent used in advanced esophageal carcinoma, has been shown to be effective and safe in western studies. Different with westerns, squamous carcinoma is the main pathological type in china patients. The investigators then initiated a prospective phase II clinical trial with irinotecan/cisplatin as the 1st line treatment in advanced esophageal carcinoma to observe the efficacy and safety of the combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | irinotecan/cisplatin | irinotecan 130mg/m2 d1 cisplatin 30mg/m2, d1,d2 every 3 weeks |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2011-08-01
- Completion
- 2012-08-01
- First posted
- 2010-01-20
- Last updated
- 2010-01-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01051765. Inclusion in this directory is not an endorsement.